Lay summary
Type 1 diabetes (T1D) affects approximately 25,000 New Zealanders. T1D requires intensive self-management of glucose to reduce risks of complications. Māori and Pacific with T1D experience significant inequities under the current model of care, including access to insulin pumps. New technologies have significant potential to enable more people with T1D to achieve recommended glucose targets while also addressing inequities. Pharmac have recently announced they will launch a call for proposals to fund continuous glucose monitors (CGM). Thus an equitable roll out of funded CGM access in New Zealand has significant potential to address inequities amongst people with T1D. This project will evaluate the extent to which the roll out of funded CGM access in New Zealand is equity based. It will identify best practice within the regions best addressing equity within the CGM roll out and support regions struggling to achieve equity by sharing best practice inter-regionally.